Big Pharma Split Corp.
PRM.TO · TSX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.45 | 0.90 | -0.14 | -0.00 |
| FCF Yield | -8.68% | 70.88% | 5.13% | -47.58% |
| EV / EBITDA | 1,192.47 | -195.00 | 9.87 | 6.66 |
| Quality | ||||
| ROIC | 0.05% | -0.26% | 53.70% | 28.77% |
| Gross Margin | 82.91% | 100.00% | 89.31% | 93.36% |
| Cash Conversion Ratio | 2.41 | -18.38 | 0.47 | -2.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.20% | -61.25% | 8.42% | 30.09% |
| Free Cash Flow Growth | -110.92% | 950.88% | 112.54% | -306.98% |
| Safety | ||||
| Net Debt / EBITDA | 493.62 | -73.37 | 2.87 | 2.77 |
| Interest Coverage | 0.02 | -0.28 | 4.14 | 5.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.77 | -0.37 |
| Cash Conversion Cycle | 19.10 | -203.88 | 525.01 | -1,329.14 |